公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2012 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 | Ohashi K; Sequist L.V; Arcila M.E; Moran T; Chmielecki J; Lin Y.-L; Pan Y; Wang L; De Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; CHIH-HSIN YANG ; Miller V.A; Riely G.J; Kris M.G; Engelman J.A; Vnencak-Jones C.L; Dias-Santagata D; Ladanyi M; Pao W. | Proceedings of the National Academy of Sciences of the United States of America | 389 | 366 | |
2017 | Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial | Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG ; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. | Journal of Thoracic Oncology | 19 | 19 | |
2012 | Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma | Girard N; Sima C.S; Jackman D.M; Sequist L.V; Chen H; CHIH-HSIN YANG ; Ji H; Waltman B; Rosell R; Taron M; Zakowski M.F; Ladanyi M; Riely G; Pao W. | European Respiratory Journal | 75 | 90 | |
2019 | Osimertinib in patients with T790M mutation-positive, advanced non–small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies | Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG ; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. | Cancer | 120 | 111 | |
2018 | Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study | Gadgeel S.M; Stevenson J.P; Langer C.J; Gandhi L; Borghaei H; Patnaik A; Villaruz L.C; Gubens M; Hauke R; CHIH-HSIN YANG ; Sequist L.V; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V. | Lung Cancer | 69 | 60 | |
2019 | Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation | CHIH-HSIN YANG ; Gadgeel S.M; Sequist L.V; Wu C.-L; Papadimitrakopoulou V.A; Su W.-C; Fiore J; Saraf S; Raftopoulos H; Patnaik A. | Journal of Thoracic Oncology | 130 | 104 | |
2013 | Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations | Sequist L.V; CHIH-HSIN YANG ; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. | Journal of Clinical Oncology | 2727 | 2366 | |
2017 | Scientific Advances in Thoracic Oncology 2016 | Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG ; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. | Journal of Thoracic Oncology | 42 | 31 | |
2017 | Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers | Nilsson M.B; Sun H; Diao L; Tong P; Liu D; Li L; Fan Y; Poteete A; Lim S.-O; Howells K; Haddad V; Gomez D; Tran H; Pena G.A; Sequist L.V; CHIH-HSIN YANG ; Wang J; Kim E.S; Herbst R; Lee J.J; Hong W.K; Wistuba I; Hung M.-C; Sood A.K; Heymach J.V. | Science Translational Medicine | 92 | 85 |